Skip To Main Content
Mehdi Baratchian on Muck Rack

Mehdi Baratchian

As seen in: The Journal of Biological Chemistry, European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mehdi

Contact Mehdi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Supraphysiologic Testosterone Solutions for Enzalutamide-resistant Prostate Cancer

|
By Lewis Thomas, Glickman Urological, Mehdi Baratchian
| European Urology Verified
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. In this issue of European Urology, Lam et al [1] report on their investigation of supraphysiologic testosterone (SPT) in castration-resistant prostate cancer (CRPC) patient-derived xenografts (PDXs). The authors identified PDXs that demonstrate slow or suppressed growth when treated with SPT.
Open in Who Shared Issue with article?

Distinct Activation Mechanisms of NF-κB Regulator Inhibitor of NF-κB Kinase (IKK) by Isoforms of the Cell Death Regulator Cellular FLICE-like Inhibitory Protein (cFLIP)

|
By Christopher Davis, Mehdi Baratchian, South Mimms, Akira Shimizu, David Escors
| The Journal of Biological Chemistry Verified
The viral FLICE-like inhibitory protein (FLIP) protein from Kaposi sarcoma-associated herpesvirus activates the NF-κB pathway by forming a stable complex with a central region (amino acids 150–272) of the inhibitor of NF-κB kinase (IKK) γ subunits, thereby activating IKK. Cellular FLIP (cFLIP) forms are also known to activate the NF-κB pathway via IKK activation.
Open in Who Shared Issue with article?
See all 2 articles